ASCO 2020 – Cholangiocarcinoma

Durvalumab ± tremelimumab plus chemotherapy was well-tolerated and showed promising efficacy in chemotherapy-naïve patients with advanced biliary tract cancer. Read More ›

Page 2 of 2

Conference Correspondent Coverage is Brought to You by the Publishers of:
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications